tbuckley/cabot-search huggingface dataset:
Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study
Authors: Sydney Dubois, Bruno Tesson, Pierre-Julien Viailly, Thierry Molina, Christiane Copie-Bergman, Sylvain Mareschal, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Catherine Maingonnat, Jean-Philippe Jais, Pauline Peyrouze, Martin Figeac, Fabienne Desmots, Thierry Fest, Corinne Haioun, Thierry Lamy, Josette Briere, Tony Petrella, Danielle Canioni, Bettina Fabiani, Bertrand Coiffier, Richard Delarue, Frederic Peyrade, André Bosly, Marc Andre, Nicolas Ketterer, Gilles A. Salles, Hervé Tilly, Karen Leroy, Fabrice Jardin
Journal: Blood (2015)
Pulmonary-Tumor Induction by Transplacental Exposure to Urethane<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>
Authors: C. D. Larsen, Mrs. Lucille L. Weed, Paul B. Rhoads, Jr.
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Pulmonary-Tumor Induction by Transplacental Exposure to Urethane Get access C. D. Larsen, C. D. Larsen senior biochemist Search for other works by this author on: Oxford Academic PubMed Google Scholar Mrs. Lucille L. Weed, Mrs. Lucille L. Weed technical assistance Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul B. Rhoads, Jr. Paul B. Rhoads, Jr. National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 8, Issue 2, October 1947, Pages 63–70, https://doi.org/10.1093/jnci/8.2.63 Published: 01 October 1947 Article history Received: 28 August 1947 Published: 01 October 1947
Transplantation Following Myeloablative Cytoreduction Results in Excellent Survival, Long-Term Engraftment, and Donor Chimerism in Children with Chronic Granulomatous Disease Across Donor and Graft Sources.
Authors: Priti Tewari, Susan Wood, Paul L Martin, Suhag H Parikh, Paul Szabolcs, Kristin M Page, Timothy Driscoll, Joanne Kurtzberg, Vinod K. Prasad
Journal: Blood (2009)
Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.
Authors: Maya Koren-Michowitz, Izhar Hardan, Janina Berghoff, Galina Yshoev, Ninette Amariglio, Gideon Rechavi, Arnon Nagler, Luba Trakhtenbrot
Journal: Blood (2006)
Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL).
Authors: Andrew M. Evens, Amy Chadburn, Nicholas J. Ollberding, Sandeep S. Dave, Briseis Aschebrook-Kilfoy, Sonali M. Smith, Dennis D Weisenburger, Brian C-H Chiu
Journal: Blood (2012)
P283 An elevated PEF/FVC ratio is a marker for ILD and is associated with traction bronchiectasis on ct scan imaging
Authors: K Cranstone, J Briggs, J Park, T Nicholson, M Unstead
Journal: Thorax (2016)

<h3>Introduction</h3> ILD is physiologically characterised by restrictive ventilatory pattern, impaired gas exchange, maintained airway patency and increased elastic lung recoil pressure. Spirometric values are often well-preserved but the shape of the flow volume (FVL) can suggest enhanced mechanical emptying of the lungs. Previously spirometry has identified upper airways obstruction,<sup>1</sup> but limited data exists for the use of an index to describe possible ILD. <h3>Method</h3> Retrospective PFT data was analysed (n = 119). The slope of the line from PEF to RV (PEF/FVC ratio) was calculated and correlated against other PFT variables. Pearson’s correlation was applied between the ratio and markers of ILD, data from table previously presented at the ARPT conference 2015*. 30 patients (27&amp;male;, 3&amp;female;) were selected for CT analysis and qualitative verification of Traction Bronchiectasis (TBX). CT scan had to be within 6 months of PFTs, FVC &gt;70% predicted and a PEF/FVC &gt; 2.0 (range 2.11–4.36). Information on location within the lung and level of severity was obtained. <h3>Results</h3> Of the 30 patients, 27 were found to have TBX, (3 mild, 17 moderate and 8 severe), 3 patients had no evidence of TBX. No correlation was found between magnitude of PEF/FVC and severity of TBX. <h3>Conclusion</h3> Structural changes from TBX may cause stenting of the airways from fibrotic tissue, holding them open during forced expiration.<sup>2</sup> Our volume corrected PEF/FVC predicts reduced TLC and RV percent predicted, indicating reduced lung volumes and lung stiffness in patients with restrictive lung disease. The evidence of TBX on CT imaging supports the hypothesis that airways are held open during forced expiration, allowing increased efficiency of lung emptying in patients with a PEF/FVC &gt;2.0. The magnitude of the ratio did not correlate with TBX severity but further work to determine a cut off ratio to predict future fibrosis is required. This index may be of use indicate a value beyond which TBX is likely to be present. <h3>Reference</h3> Empey DW. Assessment of upper airway obstruction. <i>BMJ</i> 1972;<b>3</b>:503–505. Woodring JH, Barrett PA, Rehm SR, <i>et al</i>. Acquired tracheomegaly in adults as a complication of diffuse pulmonary fibrosis. <i>AJR</i> 1989;<b>152</b>(4):743–747.
Subcutaneous Immunoglobulin Substitutions in Previously Untreated (PUPs) and Treated Patients (PTPs) Result in Rapid Improvement of Total and Serum IgG Levels - a Novel Substitution Protocol for PUPs.
Authors: Christoph Königs, Dominik Dunsch, Richard Linde, Thomas Klingebiel, Wolfhart Kreuz
Journal: Blood (2004)
TGF-β1, in Synergy with M-CSF Induce Generation of a Novel Type of Human Cord Blood Dendritic Cell That Is Both Anti-Inflammatory and Capable of Ex-Vivo Expansion of Myeloid Progenitor Cells.
Authors: Geling Li, Timothy B. Campbell, Barbara Graham-Evans, Scott Cooper, Hal E. Broxmeyer
Journal: Blood (2005)
Genome-Wide Association Study Identifies Multiple Genetic Loci for Activated Partial Thromboplastin Time and Prothrombin Time
Authors: Weihong Tang, Mary Cushman, Christine Schwienbacher, Lorna M López, Yoav Ben-Shlomo, Saonli Basu, Martin Gögele, Gail Davies, Gordon Lowe, James S Pankow, Albert Tenesa, Claudia Volpato, Ann Rumley, Alan Gow, Cosetta Minelli, John W.G. Yarnell, David Porteous, John M Starr, Eric Boerwinkle, Peter M Visscher, Peter P Pramstaller, Ian J Deary, Andrew A Hicks, Aaron R Folsom
Journal: Blood (2010)
Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).
Authors: Elias Jabbour, Antoine Harb, Francis Giles, Jorge Cortes, Sherry Pierce, Jianqin Shan, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2006)
Arteriography for Lower Gastrointestinal Hemorrhage
Authors: Mark Tulchinsky
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).
Authors: Philipp Hemmati, Theis Terwey, Gero Massenkeil, Philipp D. le Coutre, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold
Journal: Blood (2008)
Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.
Authors: Cynthia L. Toze, Donna E. Hogge, Michael J. Barnett, Thomas J. Nevill, Stephen H. Nantel, Heather J. Sutherland, John D. Shepherd, Kevin W. Song, Donna L. Forrest, Julye C. Lavoie, Joseph M. Connors, Randy D. Gascoyne, Nicholas J. Voss, Clayton A. Smith
Journal: Blood (2004)
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma
Authors: Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Nathan Fowler, Loretta J. Nastoupil, Tanya Siddiqi, Susan Blumel, Emily K. Pauli, Kathy Cutter, Warner Tse, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Swaroop Vakkalanka, Srikant Viswanadha, Susan O'Brien
Journal: Blood (2014)
Differential MLL Interaction and H3K4me3 Mark Maintenance at PU.1 Regulatory Region by AML Translocations-Associated Oncoproteins AML1-ETO and CBFβ-SMMHC.
Authors: Gang Huang, Xiaomei Yan, Xinghui Zhao, Yalan Rao, Goro Sashida, Rajeana Bowie
Journal: Blood (2009)
Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
Authors: Catherine M. Alfano, Juan Peng, Rebecca R. Andridge, Monica E. Lindgren, Stephen P. Povoski, Adele M. Lipari, Doreen M. Agnese, William B. Farrar, Lisa D. Yee, William E. Carson, Janice K. Kiecolt-Glaser
Journal: Journal of Clinical Oncology (2017)

Purpose The sequelae of cancer treatment may increase systemic inflammation and create a phenotype at increased risk of functional decline and comorbidities, leading to premature mortality. Little is known about how this trajectory compares with natural aging among peers of the same age without cancer. This longitudinal study investigated proinflammatory cytokines and comorbidity development over time among breast cancer survivors and a noncancer control group. Methods Women (N = 315; 209 with breast cancer and 106 in the control group) were recruited at the time of their work-up for breast cancer; they completed the baseline questionnaire, interview, and blood draw (lipopolysaccharide-stimulated production of interleukin [IL] -6, tumor necrosis factor-α, and IL-1β). Measures were repeated 6 and 18 months after primary cancer treatment (cancer survivors) or within a comparable time frame (control group). Results There were no baseline differences in comorbidities or cytokines between survivors and the control group. Over time, breast cancer survivors had significantly higher tumor necrosis factor-α and IL-6 compared with the control group. Survivors treated with surgery, radiation, and chemotherapy accumulated a significantly greater burden of comorbid conditions and suffered greater pain associated with inflammation over time after cancer treatment than did the control group. Conclusion Survivors who had multimodal treatment had higher cytokines and comorbidities, suggestive of accelerated aging. Comorbidities were related to inflammation in this sample, which could increase the likelihood of premature mortality. Given that many comorbidities take years to develop, future research with extended follow-up beyond 18 months is necessary to examine the evidence of accelerated aging in cancer survivors and to determine the responsible mechanisms.
The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases the Severity of Acute Lung Injury After Allogeneic Hematopoietic Cell Transplantation.
Authors: Sabarinath Venniyil Radhakrishnan, Senthilnathan Palaniyandi, Fridrik Karlsson, Elisabeth Huber, Gerhard Hildebrandt
Journal: Blood (2012)
Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
Authors: Bhumika Patel, Caner Saygin, Bartlomiej P Przychodzen, Teodora Kuzmanovic, Cassandra M. Hirsch, Michael J. Clemente, Swapna Thota, Aziz Nazha, Sekeres A Mikkael, Jaroslaw P Maciejewski, Hetty E. Carraway
Journal: Blood (2016)
Influence of recipient's Age On the Outcome of HLA-Matched Sibling Transplants in Adult Patients with Severe Aplastic Anemia Who Conditioned with Fludarabine-Based Regimen
Authors: SeungHwan Shin, JaeHo Yoon, SeungAh Yahng, SungEun Lee, ByungSik Cho, KiSung Eom, YooJin Kim, Seok Lee, ChangKi Min, Heeje Kim, SeokGoo Cho, DongWook Kim, WooSung Min, ChongWon Park, JongWook Lee
Journal: Blood (2012)
Expression of Multidrug Resistance 1, Lung Resistance Protein and Breast Cancer Resistance Protein Genes in Chronic Lymphocytic and Chronic Myelogeneous Leukemia.
Authors: A. Ugur Ural, Ozlem Darcansoy Iseri, Pelin Kaya Mutlu, Meltem Demirel Kars, Ferit Avcu, Ufuk Gunduz
Journal: Blood (2006)
Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study.
Authors: Meletios A. Dimopoulos, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, Panayiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Costas Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Nikolaos Anagnostopoulos, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas
Journal: Blood (2009)
Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.
Authors: Abraham Avigdor, Shlomo Bulvik, Eldad Dann, Itai Levi, Galit Perez-Avraham, Noga Shemtov, Avichai Shimoni, Arnon Nagler, Isaac Ben-Bassat, Aaron Polliack
Journal: Blood (2007)
COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY”
Authors: Alessandro Levis, Daniela Maria Gioia, Laura Godio, Mauro Girotto, Bernardino Allione, Claudia Bertassello, Margherita Bonferroni, Maria Matilde Ciriello, Gianni Cametti, Giorgio Ciravegna, Antonella Ferranti, Monia Lunghi, Dario Ferrero, Roberto Freilone, Simona Gatto, Flavia Salvi, Michela Savio, Patrizia Scaravaglio, Alessandra Stacchini, Anna Tonso, Mario Boccadoro, Gianluca Gaidano, Andrea Gallamini, Umberto Vitolo, Giuseppe Saglio
Journal: Blood (2010)
Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial
Authors: Mohamad Mohty, Didier Blaise, Myriam Labopin, Noel Milpied, Sabine Furst, Reza Tabrizi, Thierry Guillaume, Stephane Vigouroux, Jean El-Cheikh, Jacques Delaunay, Steven Legouill, Philippe Moreau, Patrice Chevallier
Journal: Blood (2012)
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
Authors: Annalene Nel, Neliëtte van Niekerk, Saidi Kapiga, Linda-Gail Bekker, Cynthia Gama, Katherine Gill, Anatoli Kamali, Philip Kotze, Cheryl Louw, Zonke Mabude, Nokuthula Miti, Sylvia Kusemererwa, Hugo Tempelman, Hannelie Carstens, Brid Devlin, Michelle Isaacs, Mariëtte Malherbe, Winel Mans, Jeremy Nuttall, Marisa Russell, Smangaliso Ntshele, Marlie Smit, Leonard Solai, Patrick Spence, John Steytler, Kathleen Windle, Maarten Borremans, Sophie Resseler, Jens Van Roey, Wim Parys, Tony Vangeneugden, Ben Van Baelen, Zeda Rosenberg
Journal: New England Journal of Medicine (2016)

The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings containing either 25 mg of dapivirine or placebo. Participants inserted the rings themselves every 4 weeks for up to 24 months. The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion.A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years). The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P=0.04). There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P=0.43 for treatment-by-age interaction). Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group. Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]). However, no clear pattern was identified.Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo. (Funded by the International Partnership for Microbicides; ClinicalTrials.gov number, NCT01539226 .).
Dysregulated Macrophage Pro-Inflammatory Cytokine Production and Chronic Colitis in Mice Lacking Both Gab2 and Gab3
Authors: Tamisha Y. Vaughan-Whitley, Hikaru Nishio, Barry Imhoff, Zhengqi Wang, Silvia T. Bunting, Pamela Hankey-Giblin, Asma Nusrat, Charles A. Parkos, Kevin D. Bunting
Journal: Blood (2014)
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Authors: Nancy K Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao, Sean J Yoder, Maria E Balasis, Tania E Mesa, David A Sallman, Jeffrey E Lancet, Rami S Komrokji, Alan F List, Howard L McLeod, Melissa Alsina, Rachid Baz, Kenneth H Shain, Dana E Rollison, Eric Padron
Journal: The Lancet Oncology (2016)
Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia.
Authors: Claudia D. Baldus, Michael Radmacher, Guido Marcucci, Dieter Hoelzer, Eckhard Thiel, Clara D. Bloomfield, Wolf-Karsten Hofmann
Journal: Blood (2005)
Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF) Enhances Mapatumumab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) Against Non-Hodgkin’s Lymphoma (NHL) Cell Lines Independent of NADPH Oxidase-Derived Reactive Oxidant Intermediates (ROIs).
Authors: Lyudmyla Derby, Francisco J. Hernandez-Ilizaliturri, Brahm H. Segal, Joy Knight, Jennifer Bushey, Myron S. Czuczman
Journal: Blood (2007)
Influence Of Antithrombin Deficiency On Symptomatic Recurrent Venous Thromboembolism (VTE) In Children: A Multicenter Cohort Study
Authors: Gili Kenet, Verena Limperger, Neil A Goldenberg, Christine Heller, Susanne Holzhauer, Shoshana Revel- Vilk, Guy Young, Ulrike Nowak- Gottl
Journal: Blood (2013)
Survival of Patients Autografted for Chemosensitive Hodgkin Lymphoma After Failure of Upfront BEACOPP Escalated Versus ABVD-Like Regimens
Authors: Luciano Wannesson, Mario Bargetzi, Anne Cairoli, Dominik Heim, Urs Hess, Erika Lerch, Thomas Pabst, Christoph Renner, Panagiotis Samaras, Emanuele Zucca
Journal: Blood (2011)
Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.
Authors: Leandro De Padua Silva, Marcos de Lima, Hagop Kantarjian, Richard Champlin, Stefan Faderl, Sergio Giralt, Partow Kebriaei, Jan Davisson, Eli Estey, Guillermo Garcia-Manero, Jean-Pierre Issa, Farhad Ravandi
Journal: Blood (2007)
P0750 : Enhanced liver fibrosis (ELF) test does not predict residual cirrhosis after a sustained virological response to hepatitis C treatment
Authors: R. D’Ambrosio, E. Degasperi, M. Fraquelli, P. Riccardo, A. Aghemo, P. Lampertico, P. Bedossa, W. Rosenberg, M. Colombo
Journal: Journal of Hepatology (2015)
Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.
Authors: Eric M. Knoche, Daniel A.C. Fisher, Gregory Rippberger, Li He, Deborah M. Moore, Jonathan L. Klein, Stephen T. Oh
Journal: Blood (2012)
ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY
Authors: Daniela Bota, Annick Desjardins, Warren Mason, Howard Fine, Santosh Kesari, Steven D. Reich, Anshu Vashishtha, Nancy Levin, Mohit Trikha
Journal: Neuro-Oncology (2016)

MRZ is an irreversible, brain-penetrant, pan-proteasome inhibitor (PI) with anti-MG efficacy preclinically in vitro and in vivo. The safety, pharmocokinetics, and activity of MRZ+BEV is evaluated in BEV-naïve G4 MG patients (pts) in first or second relapse (no prior anti-angiogenic or PI therapy), in a 3+3 dose-escalation (MRZ 0.55 (6 pts), 0.7 (3 pts), and 0.8 mg/m2 (3 pts)) followed by dose-expansion (0.8 mg/m2, 24 pts). Treatments administered IV, 28-day cycles: MRZ (10 min) days 1, 8, & 15; BEV (10 mg/kg) days 1 & 15. Tumor response assessed every other cycle by RANO criteria; MRZ and BEV pharmacokinetics, and proteasome inhibition in circulating blood cells also evaluated. Data reported as of 17 May 2016; median age 55 yrs (range 27–76 yrs), 64% male, Karnofsky score ≥70. Duration of dosing 0.5–11.6 months to date; treatment ongoing in 16 pts. Study treatment-related Grade ≥3 AEs: fatigue, headache, hypertension, hallucination, confusional state, ataxia; one Grade 4 SAE (appendicitis perforated, not related to study treatment), one Grade 5 SAE (intracranial hemorrhage, BEV-related). One pt (cohort 1) had DLT (fatigue); no other DLTs occurred. N=36 for the intent-to-treat population; 30 pts efficacy evaluable by RANO criteria. Overall response (≥ partial response, PR) 39% (14/36, including 5 with complete target lesion response and 2 unconfirmed PRs); 11 stable disease, 5 progressive disease. PFS 6-months is 39%; median OS not yet reached. MGMT status known for 15 of 36 pts; 14 unmethylated (uMGMT), 1 methylated. Seven of 14 uMGMT pts achieved ≥PR; 49% PFS 6-months in uMGMT subgroup. Preliminary activity in uMGMT subgroup suggests therapeutic advantage provided by brain-penetrant PI in comparison with BEV single agent (Taal et al., 2014). MRZ+BEV combination is well tolerated with promising early signs of efficacy in recurrent G4 MG pts.
Regional Myocardial Contractility In Thalassemia Major By Magnetic Resonance Tagging
Authors: Antonella Meloni, Chiara Tudisca, Emanuele Grassedonio, Giancarlo Izzi, Maddalena Lendini, Rino Biguzzi, Graziella Filati, Aurelio Maggio, Martina Marinelli, Massimo Midiri, Massimo Lombardi, Alessia Pepe
Journal: Blood (2013)
Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.
Authors: Richard L. Piekarz, Robin Frye, Maria Turner, John Wright, Steven Allen, Mark H. Kirschbaum, Jasmine Zain, Miles Prince, Laura Hutchins, Louise C. Showe, William D. Figg, Tito Fojo, Susan E. Bates
Journal: Blood (2006)
Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma
Authors: Catherine Garnett, Chrissy Giles, Osman Ahmed, Maialen Lasa, Holger W. Auner, Donald MacDonald, Sasha Marks, David Marin, Dragana Milojkovic, Jiri Pavlu, Marco Bua, Saad Abdalla, Edward J Kanfer, Jane Apperley, Amin Rahemtulla
Journal: Blood (2012)